NANETS Symposium | Conference

Dr. Chauhan on the Role of Lutathera in NETs

October 3rd 2020

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses the role of Lutathera in neuroendocrine tumors.

Dual CDK4/6, MEK Blockade Demonstrates Synergy in PNET Models

October 2nd 2020

Combination CDK4/6 and MEK inhibition was “highly synergistic” in killing pancreatic neuroendocrine tumor cells in vitro and effectively suppressed PNET growth in mice.

Dr. Pavel on the PFS With Lanreotide Autogel in the CLARINET FORTE Trial

October 2nd 2020

Marianne Pavel, MD, discusses the progression-free survival of patients with pancreatic and midgut neuroendocrine tumors who are treated with lanreotide autogel in the phase 2 CLARINET FORTE trial.

Lutathera-Based PRRT Retreatment Shows OS Benefit With Acceptable Safety in NETs

October 2nd 2020

Retreatment with Lutathera-based peptide receptor radionuclide therapy has been shown to have an encouraging survival benefit with an acceptable safety in patients with neuroendocrine tumors.

Dr. Wolin on the Safety of Lutathera in Advanced NETs

October 2nd 2020

Edward Wolin, MD, discusses the safety profile of 177Lu-dotatate in patients with advanced neuroendocrine tumors.

Telotristat/Lutathera Combo Could Improve Outcomes in Well-Differentiated NETs

October 2nd 2020

Investigators are evaluating the combination of telotristat ethyl and Lutathera with a goal to improve progression-free survival in patients with well-differentiated neuroendocrine tumors in a randomized, phase 2 study that was highlighted during the 2020 NANETs Virtual Symposium.

Long-Term Toxicity Data Confirm the Tolerability of Lutathera in NETs

October 2nd 2020

Longer-term data demonstrated that treatment with the radiopharmaceutical Lutathera continued to show low rates of toxicity among patients with somatostatin receptor–positive neuroendocrine tumors.

Dr. Krampitz on Therapeutic Targets in pNETs

January 21st 2016

Geoffrey Krampitz, MD, Department of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, identifies tumorigenic cells and therapeutic targets in patients with pancreatic neuroendocrine tumors.

Dr. Kunz on Potential of Immunotherapy in Neuroendocrine Tumors

October 17th 2015

Pamela L. Kunz, MD, assistant professor of Medicine (Oncology), Stanford University School of Medicine, discusses the potential of immunotherapy in the treatment of patients with neuroendocrine tumors (NETs).

Everolimus Shows Robust Activity in Lung/GI NETs

October 17th 2015

Everolimus improved progression-free survival by 7.1 months compared with placebo in patients with lung/gastrointestinal (GI) neuroendocrine tumors, representing a 52% reduction in the risk of progression or death.

Lu-Dotatate Shows Unprecedented PFS in Midgut NETs

October 17th 2015

Lu-Dotatate demonstrated an unprecedented 79% reduction in the risk of progression or death compared with high-dose octreotide LAR in patients with progressive, metastatic midgut neuroendocrine tumors.

Dr. Yao on the RADIANT-4 Study for NETs of Lung or GI Origin

October 17th 2015

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses results of the RADIANT-4 study, which examined the safety and efficacy of everolimus in advanced nonfunctional neuroendocrine tumors (NETs) of lung or gastrointestinal origin.

Dr. Anthony on Treatment Benefit With Telotristat Epitrate in Patients With Carcinoid Syndrome

October 16th 2015

Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, discusses patient exit interviews from the phase III placebo-controlled TELESTAR trial, which evaluated telotristate epitrate in patients with inadequately controlled carcinoid syndrome.

Novel Drug Relieves Carcinoid Syndrome Symptoms

October 16th 2015

Telotristat etiprate, a novel serotonin synthesis inhibitor, helped reduce daily bowel movements for patients with carcinoid syndrome no longer responding to standard-of-care therapies.

Combining Chemo With mTOR Inhibitors Shows Promise in pNETS

October 16th 2015

Combining the chemotherapy streptozotocin with drugs that target the mTOR pathway may be an effective way to treat pancreatic neuroendocrine tumors.

Biomarker Needed for CAPTEM Regimen in Metastatic Pancreatic NETs

October 16th 2015

The efficacy of several predictive markers previously thought to determine which patients might respond to temozolomide-based therapy could not be validated for patients with pancreatic neuroendocrine tumors.

Dr. Strosberg on NETTER-1 Trial Results for Midgut NETs

October 16th 2015

Jonathan R. Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses results of the phase III NETTER-1 trial for midgut neuroendocrine tumors.

Full Surgical Resection Should Be Performed Whenever Possible for Gastroenteropancreatic NETs

October 16th 2015

Full surgical resection of gastroenteropancreatic neuroendocrine tumors is associated with a greater than 90% survival rate at five years.

Dr. Liu on Medical Advancements for Neuroendocrine Tumors

October 16th 2015

Eric Liu, MD, FACS, surgeon, neuroendocrine tumors, Rocky Mountain Cancer Centers, discusses some of the most recent medical advancements in the field of neuroendocrine tumors.

Dr. Metz on Increasing Incidence of Neuroendocrine Tumors

October 16th 2015

David C. Metz, MD, gastroenterologist, University of Pennsylvania School of Medicine, associate chief, Medical Affairs, Division of Gastroenterology, discusses the increasing incidence of neuroendocrine tumors.